Literature DB >> 23975176

Stem cell mobilization in HIV seropositive patients with lymphoma.

Alessandro Re1, Chiara Cattaneo, Cristina Skert, Pascual Balsalobre, Mariagrazia Michieli, Mark Bower, Andrés J M Ferreri, Marcus Hentrich, José M Ribera, Bernardino Allione, Philipp Schommers, Silvia Montoto, Camillo Almici, Pierino Ferremi, Mario Mazzucato, Salvatore Gattillo, Salvatore Casari, Michele Spina, José L Diez-Martin, Umberto Tirelli, Giuseppe Rossi.   

Abstract

High-dose chemotherapy with autologous peripheral blood stem cell rescue has been reported as feasible and effective in HIV-associated lymphoma. Although a sufficient number of stem cells seems achievable in most patients, there are cases of stem cell harvest failure. The aim of this study was to describe the mobilization policies used in HIV-associated lymphoma, evaluate the failure rate and identify factors influencing mobilization results. We analyzed 155 patients who underwent attempted stem cell mobilization at 10 European centers from 2000-2012. One hundred and twenty patients had non-Hodgkin lymphoma and 35 Hodgkin lymphoma; 31% had complete remission, 57% chemosensitive disease, 10% refractory disease, 2% untested relapse. Patients were mobilized with chemotherapy + G-CSF (86%) or G-CSF alone (14%); 73% of patients collected >2 and 48% >5 × 10(6) CD34(+) cells/kg. Low CD4+ count and refractory disease were associated with mobilization failure. Low CD4(+) count, low platelet count and mobilization with G-CSF correlated with lower probability to achieve >5 × 10(6) CD34(+) cells/kg, whereas cyclophosphamide ≥ 3 g/m(2) + G-CSF predicted higher collections. Circulating CD34(+) cells and CD34/WBC ratio were strongly associated with collection result. HIV infection alone should not preclude an attempt to obtain stem cells in candidates for autologous transplant as the results are comparable to the HIV-negative population.

Entities:  

Mesh:

Year:  2013        PMID: 23975176      PMCID: PMC3815178          DOI: 10.3324/haematol.2013.089052

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  42 in total

1.  Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Authors:  U Narayanasami; R Kanteti; J Morelli; A Klekar; A Al-Olama; C Keating; C O'Connor; E Berkman; J K Erban; K A Sprague; K B Miller; D P Schenkein
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.

Authors:  David Serrano; Rafael Carrión; Pascual Balsalobre; Pilar Miralles; Juan Berenguer; Ismael Buño; Alfonso Gómez-Pineda; José M Ribera; Eulogio Conde; José L Díez-Martín
Journal:  Exp Hematol       Date:  2005-04       Impact factor: 3.084

3.  Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support.

Authors:  K A Schulman; R Birch; B Zhen; N Pania; C H Weaver
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

4.  A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF.

Authors:  L Meldgaard Knudsen; L Jensen; E Gaarsdal; K Nikolaisen; H E Johnsen
Journal:  Bone Marrow Transplant       Date:  2000-10       Impact factor: 5.483

5.  Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease.

Authors:  R T Schooley; J Mladenovic; A Sevin; S Chiu; S A Miles; R J Pomerantz; T B Campbell; D Bell; D Ambruso; R Wong; A Landay; R W Coombs; L Fox; M Kamoun; J Jacovini
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

6.  CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.

Authors:  T F Neal; H K Holland; C M Baum; F Villinger; A A Ansari; R Saral; J R Wingard; W H Fleming
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

7.  Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients.

Authors:  E M Sloand; N S Young; T Sato; P Kumar; S Kim; F F Weichold; J P Maciejewski
Journal:  AIDS       Date:  1997-11       Impact factor: 4.177

Review 8.  Autologous stem cell transplantation in lymphoma.

Authors:  Norbert Schmitz; Christian Buske; Christian Gisselbrecht
Journal:  Semin Hematol       Date:  2007-10       Impact factor: 3.851

9.  Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.

Authors:  R E Walker; R I Parker; J A Kovacs; H Masur; H C Lane; S Carleton; L E Kirk; H R Gralnick; A S Fauci
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

10.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  9 in total

1.  Autograft HIV-DNA load predicts HIV-1 peripheral reservoir after stem cell transplantation for AIDS-related lymphoma patients.

Authors:  Stefania Zanussi; Maria Teresa Bortolin; Chiara Pratesi; Rosamaria Tedeschi; Giancarlo Basaglia; Luciano Abbruzzese; Mario Mazzucato; Michele Spina; Emanuela Vaccher; Umberto Tirelli; Maurizio Rupolo; Mariagrazia Michieli; Michele Di Mascio; Paolo De Paoli
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

2.  Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma.

Authors:  R Ramaswami; A Dalla Pria; K Parker; S McCann; E J Kanfer; M Nelson; M Bower
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

3.  Managing HIV and Hodgkin lymphoma in the twenty-first century.

Authors:  James Aries; Silvia Montoto
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

4.  A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.

Authors:  Gaofeng Zheng; Jingsong He; Zhen Cai; Donghua He; Yi Luo; Jimin Shi; Guoqing Wei; Jie Sun; Weiyan Zheng
Journal:  Oncol Lett       Date:  2019-12-03       Impact factor: 2.967

5.  CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes with oxygen dosage.

Authors:  Marvin Heyboer; Tatyana N Milovanova; Susan Wojcik; William Grant; Mary Chin; Kevin R Hardy; David S Lambert; Christopher Logue; Stephen R Thom
Journal:  Stem Cell Res       Date:  2014-02-28       Impact factor: 2.020

Review 6.  Current knowledge on HIV-associated Plasmablastic Lymphoma.

Authors:  Michele Bibas; Jorge J Castillo
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

7.  B- and T-lymphocyte number and function in HIV+/HIV- lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  Diego Bertoli; Alessandro Re; Marco Chiarini; Alessandra Sottini; Federico Serana; Viviana Giustini; Aldo M Roccaro; Chiara Cattaneo; Luigi Caimi; Giuseppe Rossi; Luisa Imberti
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

Review 8.  Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection.

Authors:  Tetsuo Tsukamoto
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

9.  Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice.

Authors:  David L DiGiusto; Rodica Stan; Amrita Krishnan; Haitang Li; John J Rossi; John A Zaia
Journal:  Viruses       Date:  2013-11-22       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.